Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Cash & Equivalents (2019 - 2025)

Cresco Labs (CRLBF) has disclosed Cash & Equivalents for 5 consecutive years, with $137.6 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Cash & Equivalents rose 33.0% year-over-year to $137.6 million, compared with a TTM value of $137.6 million through Dec 2024, up 33.0%, and an annual FY2024 reading of $137.6 million, up 33.0% over the prior year.
  • Cash & Equivalents was $137.6 million for Q4 2024 at Cresco Labs, up from $103.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $223.5 million in Q4 2021 and bottomed at $103.4 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $144.0 million, with a median of $136.3 million recorded in 2020.
  • The sharpest move saw Cash & Equivalents soared 63.96% in 2021, then tumbled 46.61% in 2022.
  • Year by year, Cash & Equivalents stood at $136.3 million in 2020, then skyrocketed by 63.96% to $223.5 million in 2021, then crashed by 46.61% to $119.3 million in 2022, then fell by 13.33% to $103.4 million in 2023, then surged by 33.0% to $137.6 million in 2024.
  • Business Quant data shows Cash & Equivalents for CRLBF at $137.6 million in Q4 2024, $103.4 million in Q4 2023, and $119.3 million in Q4 2022.